These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34541912)

  • 41. Efficacy of topical versus intradermal injection of Tranexamic Acid In Egyptian melasma Patients: A randomised clinical trial.
    Badran AY; Ali AU; Gomaa AS
    Australas J Dermatol; 2021 Aug; 62(3):e373-e379. PubMed ID: 33782959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Use of Tranexamic Acid to Prevent and Treat Post-Inflammatory Hyperpigmentation.
    Lindgren AL; Austin AH; Welsh KM
    J Drugs Dermatol; 2021 Mar; 20(3):344-345. PubMed ID: 33683077
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral Tranexemic Acid With Triple Combination Cream (Flucinolone+Hydroquinone+Tretinoin) Versus Triple Combination Cream Alone In Treatment Of Melasma.
    Basit A; Rahman A; Uddin R
    J Ayub Med Coll Abbottabad; 2021; 33(2):293-298. PubMed ID: 34137548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma.
    Sahu PJ; Singh AL; Kulkarni S; Madke B; Saoji V; Jawade S
    J Cosmet Dermatol; 2020 Jun; 19(6):1456-1462. PubMed ID: 32346962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies.
    Sonthalia S; Daulatabad D; Sarkar R
    Indian J Dermatol Venereol Leprol; 2016; 82(3):262-72. PubMed ID: 27088927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser.
    Kato H; Araki J; Eto H; Doi K; Hirai R; Kuno S; Higashino T; Yoshimura K
    Dermatol Surg; 2011 May; 37(5):605-10. PubMed ID: 21457392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of combined fractional CO
    Tawfic SO; Abdel Halim DM; Albarbary A; Abdelhady M
    Lasers Surg Med; 2019 Jan; 51(1):27-33. PubMed ID: 30431171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial.
    Lee JH; Park JG; Lim SH; Kim JY; Ahn KY; Kim MY; Park YM
    Dermatol Surg; 2006 May; 32(5):626-31. PubMed ID: 16706756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting delivery and minimizing epidermal diffusion of tranexamic acid by hyaluronic acid-coated liposome nanogels for topical hyperpigmentation treatment.
    Liu Y; Han Y; Zhu T; Wu X; Yu W; Zhu J; Shang Y; Lin X; Zhao T
    Drug Deliv; 2021 Dec; 28(1):2100-2107. PubMed ID: 34596008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and development of tranexamic acid loaded film-forming gel to alleviate melasma.
    Chevala NT; Dsouza JA; Saini H; Kumar L
    J Cosmet Dermatol; 2022 Dec; 21(12):6863-6874. PubMed ID: 36181344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The emerging importance of tranexamic acid in dermatology.
    Forbat E; Al-Niaimi F; Ali FR
    Clin Exp Dermatol; 2020 Jun; 45(4):445-449. PubMed ID: 31663643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The top 10 cosmeceuticals for facial hyperpigmentation.
    Searle T; Al-Niaimi F; Ali FR
    Dermatol Ther; 2020 Nov; 33(6):e14095. PubMed ID: 32720446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topical Stabilized Cysteamine as a New Treatment for Hyperpigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Lentigines.
    Desai S; Hartman C; Grimes P; Shah S
    J Drugs Dermatol; 2021 Dec; 20(12):1276-1279. PubMed ID: 34898155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brightening and Improvement of Facial Skin Quality in Healthy Female Subjects With Moderate Hyperpigmentation or Dark Spots and Moderate Facial Aging.
    Serra M; Bohnert K; Narda M; Granger C; Sadick N
    J Drugs Dermatol; 2018 Dec; 17(12):1310-1315. PubMed ID: 30586263
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Chemical peeling for treatment of Melasma, pigmentary disorders and hyperpigmentation : Indications, effectivity and risks].
    Borelli C; Fischer S
    Hautarzt; 2020 Dec; 71(12):950-959. PubMed ID: 33141276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Safety and Efficacy of Treatment With a 1,927-nm Diode Laser With and Without Topical Hydroquinone for Facial Hyperpigmentation and Melasma in Darker Skin Types.
    Vanaman Wilson MJ; Jones IT; Bolton J; Larsen L; Fabi SG
    Dermatol Surg; 2018 Oct; 44(10):1304-1310. PubMed ID: 29659405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Evaluation of a 4% Hydroquinone + 1% Retinol Treatment Regimen for Improving Melasma and Photodamage in Fitzpatrick Skin Types III-VI.
    Rendon MI; Barkovic S
    J Drugs Dermatol; 2016 Nov; 15(11):1435-1441. PubMed ID: 28095558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluating the Safety and Efficacy of a Topical Formulation Containing Epidermal Growth Factor, Tranexamic Acid, Vitamin C, Arbutin, Niacinamide and Other Ingredients as Hydroquinone 4% Alternatives to Improve Hyperpigmentation: A Prospective, Randomized, Controlled Split Face Study.
    Kalasho BD; Minokadeh A; Zhang-Nunes S; Zoumalan RA; Shemirani NL; Waldman AR; Pletzer V; Zoumalan CI
    J Cosmet Sci; 2020; 71(5):263-290. PubMed ID: 33022197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A review of combined treatments for melasma involving energy-based devices and proposed pathogenesis-oriented combinations.
    Mehrabi JN; Bar-Ilan E; Wasim S; Koren A; Zusmanovitch L; Salameh F; Isman Nelkenbaum G; Horovitz T; Zur E; Song Lim T; Mashiah J; Artzi O
    J Cosmet Dermatol; 2022 Feb; 21(2):461-472. PubMed ID: 33794033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparing the efficacy of Myjet-assisted tranexamic acid and vitamin C in treating melasma: A split-face controlled trial.
    Zhao H; Li M; Zhang X; Li L; Yan Y; Wang B
    J Cosmet Dermatol; 2020 Jan; 19(1):47-54. PubMed ID: 31479196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.